ADPT

Business Context and Reporting Period

Company: Adaptive Biotechnologies Corp (ADPT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Adaptive Biotechnologies operates two primary segments: the MRD Business, focused on the clonoSEQ clinical diagnostic test for minimal residual disease in lymphoid malignancies, and the Immune Medicine (IM) Business, focused on drug discovery and development for cancer and autoimmune diseases. The company reorganized its operations in 2024 to align with these two segments.

Key Financial Metrics

Segment Performance:
- MRD Revenue: $145.5 million (42% increase YoY), driven by a 35% increase in clonoSEQ test volume and $12.5 million in milestone revenue.
- IM Revenue: $33.4 million (51% decrease YoY), primarily due to reduced amortization of the Genentech upfront payment and lower collaboration revenue.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 5% to $179.0 million. The MRD segment grew significantly, while the IM segment declined due to the recognition of a $10.0 million Genentech milestone in 2023 which did not recur in 2024.
• Expense Reduction: Operating expenses decreased by $55.8 million (14%) to $341.5 million. This was driven by workforce reductions, laboratory consolidation, and reduced marketing spend.
• Restructuring & Impairment: The company recognized $9.2 million in restructuring costs in 2024, including $7.2 million in non-cash asset impairment charges related to vacated leased space and halted software enhancements. This compares to $25.4 million in impairment charges in 2023.
• Liquidity: Cash and marketable securities decreased by $90.4 million to $256.0 million, reflecting operating cash outflows of $95.2 million.

Guidance, Outlook, and Risks

Management Commentary & Outlook:
- The company expects to continue investing in the MRD business to drive market penetration and in the IM business to advance therapeutic candidates.
- Management believes current cash resources are sufficient to fund operations for at least the next 12 months.
- The company is transitioning from NextSeq to NovaSeq X sequencers in late 2025 to reduce operational costs.

Key Risks & Contingencies:
- Regulatory: The FDA's final rule on Laboratory Developed Tests (LDTs) may require additional regulatory compliance and costs starting in 2025.
- Collaboration Dependency: Significant revenue and future milestones depend on the Genentech collaboration; Genentech controls clinical development and commercialization.
- Reimbursement: Future Medicare payment rates are uncertain, and coverage decisions by private payors are critical for the MRD business.
- Profitability: The company has an accumulated deficit of $1.3 billion and expects to incur losses in the future as it invests in R&D.

Investor Verification Checklist

• Genentech Revenue Recognition: Verify the assumptions used for the proportional performance model regarding the Genentech collaboration, as this significantly impacts IM revenue volatility.
• MRD Test Volume vs. Revenue: Confirm the correlation between the reported 35% increase in test volume and the revenue growth, considering the impact of the new Medicare CLFS rate of $2,007 per test effective January 2025.
• OrbiMed Revenue Interest Liability: Review the terms of the Revenue Interest Purchase Agreement, specifically the "Return Cap" and the impact of forecasted revenue changes on interest expense.
• LDT Regulatory Compliance: Assess the potential financial impact of the FDA's LDT final rule on the company's ability to offer clonoSEQ as a Laboratory Developed Test for non-FDA cleared indications.
• Cash Burn Rate: Monitor the trajectory of operating cash flows to ensure the $256 million cash balance remains sufficient for the projected 12-month runway.